Bachisio Ziccheddu

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma

The paper identifies genomic and transcriptional changes in multiple myeloma cells that drive resistance to anti-BCMA therapies, termed 'plasma cell identity escape'.

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma

This study analyzes whole-genome sequencing data from multiple myeloma patients to show that the timing of genetic events, not just their presence, affects clinical outcomes.

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma.

This study identifies biallelic CD38 loss as a mechanism of resistance to anti-CD38 antibodies in multiple myeloma, with specific mutations affecting antibody efficacy.

RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant B-Cell Lymphoma

Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies

The paper investigates the mutagenic impact of radiotherapy in hematologic malignancies and finds that RT contributes to the ID8 mutational signature, which is associated with treatment resistance and relapse.

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies

The paper shows that genomic antigen escape mechanisms in multiple myeloma occur during CAR-T/TCE treatment, not pre-existing, and emerge after one year of therapy.

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.

This study identifies genomic and immune factors associated with resistance to anti-CD38 therapy in multiple myeloma patients.

Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma

This study shows copy number signatures predict chromothripsis in multiple myeloma and link to poor clinical outcomes using whole genome and exome sequencing data.